Pharma BD Deal Intelligence
Daiichi Sankyo hands China commercialization of an approved FLT3 inhibitor to Innovent
Full analysis, sources & comparables →Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for commercialization of VANFLYTA (quizartinib) in China. Innovent holds sole commercialization rights in China and leads market promotion, while Daiichi Sankyo remains responsible for development, manufacturing and supply. VANFLYTA is a FLT3 inhibitor approved in Japan, the United States and Europe for relapsed or refractory FLT3-ITD positive acute myeloid leukemia, and was approved in China in June 2026 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for newly diagnosed FLT3-ITD positive AML. VANFLYTA becomes the 20th product in Innovent's commercialized portfolio. Financial terms were not disclosed.
Acute myeloid leukemia with FLT3-ITD mutations carries a poor prognosis and high relapse risk. VANFLYTA (quizartinib) was approved in China in June 2026 in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation, for newly diagnosed FLT3-ITD positive AML.
Innovent gains sole China commercialization rights to VANFLYTA, its 20th commercialized product, while Daiichi Sankyo keeps development, manufacturing and supply. Because the asset is already approved in China as of June 2026, the deal converts regulatory success into commercial reach without development risk. Financial terms were not disclosed.
Daiichi Sankyo hands China commercialization of an approved FLT3 inhibitor to Innovent
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Innovent Biologics, Inc. / Daiichi Sankyo Company, Limited (this deal) | 2026 | — | 64 |
| Innovent Biologics, Inc. / Laekna Therapeutics Shanghai Co., Ltd. | 2021 | — | — |
| Innovent Biologics, Inc. / Chipscreen Biosciences | 2019 | — | — |
| Innovent Biologics, Inc. / Shenogen Pharma Group Ltd. | 2019 | — | — |
| Innovent Biologics, Inc. / NeoCura Bio-Medical Technology Co., Ltd. | 2021 | — | — |
| Innovent Biologics, Inc. / Bolt Biotherapeutics, Inc. | 2021 | — | — |
| Innovent Biologics, Inc. / AnHeart Therapeutics Co., Ltd. | 2021 | — | — |